A Kohlmann
Overview
Explore the profile of A Kohlmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soria J, Fulop A, Maciel C, Fischer J, Girotto G, Lago S, et al.
Ann Oncol
. 2017 Oct;
28(12):3028-3036.
PMID: 29045535
Background: Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated...
2.
Ryan S, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, et al.
Leukemia
. 2016 May;
30(9):1824-31.
PMID: 27168466
Intrachromosomal amplification of chromosome 21 (iAMP21) identifies a high-risk subtype of acute lymphoblastic leukaemia (ALL), requiring intensive treatment to reduce their relapse risk. Improved understanding of the genomic landscape of...
3.
Soverini S, De Benedittis C, Papayannidis C, Polakova K, Venturi C, Russo D, et al.
Leukemia
. 2016 Feb;
30(7):1615-9.
PMID: 26867670
No abstract available.
4.
Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerova K, Nadarajah N, et al.
Leukemia
. 2015 Jul;
30(4):973-6.
PMID: 26220041
No abstract available.
5.
Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E, et al.
Leukemia
. 2014 Sep;
28(12):2292-9.
PMID: 25212276
To study clonal evolution in chronic myeloid leukemia (CML), we searched for BCR-ABL-independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph-positive clones in 29 chronic-phase CML patients by targeted...
6.
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, et al.
Blood Cancer J
. 2014 Jan;
4:e173.
PMID: 24413067
High brain and acute leukemia, cytoplasmic (BAALC) expression defines an important risk factor in cytogenetically normal acute myeloid leukemia (CN-AML). The prognostic value of BAALC expression in relation to other...
7.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al.
Leukemia
. 2013 Nov;
28(2):241-7.
PMID: 24220272
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944...
8.
Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al.
Leukemia
. 2013 Oct;
28(1):108-17.
PMID: 24113472
We analyzed a large cohort of 1160 untreated CLL patients for novel genetic markers (SF3B1, NOTCH1, FBXW7, MYD88, XPO1) in the context of molecular, immunophenotypic and cytogenetic data. NOTCH1 mutations...
9.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, et al.
Leukemia
. 2013 Sep;
28(4):794-803.
PMID: 24056881
The prognostic impact of mutations in the CCAAT/enhancer binding protein α (CEBPA) gene was evaluated in the context of concomitant molecular mutations and cytogenetic aberrations in acute myeloid leukemia (AML)....
10.
Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, et al.
Leukemia
. 2013 Aug;
28(1):129-37.
PMID: 23958918
We studied the utility and clinical relevance of RUNX1 (runt-related transcription factor 1) mutations and their application as residual disease detection markers using next-generation deep-sequencing. Mutation screening was prospectively performed...